Kingdon Capital Management L.L.C. Has $3.15 Million Stock Holdings in Jasper Therapeutics, Inc. $JSPR

Kingdon Capital Management L.L.C. boosted its position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 93.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,324,845 shares of the company’s stock after purchasing an additional 640,138 shares during the period. Kingdon Capital Management L.L.C. owned about 8.15% of Jasper Therapeutics worth $3,153,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Acadian Asset Management LLC bought a new stake in Jasper Therapeutics in the first quarter valued at approximately $46,000. Marex Group plc acquired a new stake in Jasper Therapeutics during the 2nd quarter valued at $74,000. Engineers Gate Manager LP bought a new position in Jasper Therapeutics during the second quarter worth $78,000. XTX Topco Ltd acquired a new position in shares of Jasper Therapeutics in the second quarter valued at $152,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Jasper Therapeutics during the 3rd quarter worth about $96,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Thursday, January 22nd. Rodman & Renshaw started coverage on shares of Jasper Therapeutics in a research report on Tuesday, January 13th. They set a “buy” rating and a $17.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Jasper Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $19.88.

Jasper Therapeutics Stock Down 3.9%

JSPR opened at $1.22 on Monday. The stock has a market capitalization of $34.14 million, a price-to-earnings ratio of -0.21 and a beta of 3.08. Jasper Therapeutics, Inc. has a twelve month low of $1.11 and a twelve month high of $7.19. The company has a 50-day simple moving average of $1.44 and a 200 day simple moving average of $1.89.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.